INTRODUCTION
============

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic virus, which causes pneumonia, originated in Wuhan, China, in 2019 and is spreading rapidly to other countries \[[@B1]\]. By April 11, 2020, 1,610,909 cases of coronavirus disease 2019 (COVID-19) had been confirmed in 213 countries, and 99,690 COVID-19 patients had died worldwide. The Chinese Center for Disease Control and Prevention reported 81% as mild cases, 14% as severe cases, and 5% as critical cases \[[@B2]\].

Diabetes mellitus (DM) has an estimated prevalence of 9.3% globally, and is a serious disease that impacts the health status associated with other diseases \[[@B3]\]. In a population-based cohort study, DM was clearly shown to be associated with increased mortality from pneumonia \[[@B4]\], and hyperglycemia on admission is associated with poor clinical outcome for both diabetic and nondiabetic patients with community-acquired pneumonia \[[@B5]\]. Respiratory tract infections, including bacterial pneumonia, influenza, and tuberculosis, are more common, and are more serious in patients with DM than in those without DM \[[@B6]\]. The pathophysiology of increased mortality in diabetic patients with pneumonia is as follows: (1) decreased T lymphocyte response; (2) decreased neutrophil function; (3) depression of the antioxidant system; and (4) disorders of humoral immunity by the complement system \[[@B6]\].

Previous studies reported that 25% to 45% of patients with COVID-19 have more than one coexisting disorder. Among them, about 10% of patients in China have DM \[[@B7][@B8]\]. A recent study showed that diabetic patients are more susceptible to an inflammatory storm, eventually leading to rapid progression and poor prognosis in COVID-19 patients \[[@B9]\].

In this study, we determined the clinical characteristics of COVID-19 patients with DM compared to those without DM. In addition, we analyzed the severity and clinical outcomes of COVID-19 patients with DM according to age, glycemic control status, and medications.

METHODS
=======

Study design and subjects
-------------------------

We performed a retrospective cohort study of 117 patients with SARS-CoV-2 infection hospitalized at Yeungnam University Medical Center, in Daegu, South Korea. This study was conducted in accordance with the tenets of the Declaration of Helsinki, and was reviewed and approved by the Institutional Review Board of Yeungnam University Hospital (YUH IRB 2020-03-057). The requirement for informed consent was waived because of the retrospective study design.

During the study period, all consecutive adult patients (age \>18 years) with SARS-CoV-2 infection admitted to the hospital were eligible for inclusion. SARS-CoV-2 infection was confirmed by real-time reverse transcriptase-polymerase chain reaction assay of nasal and pharyngeal swab samples. Patients who were taken to other hospitals and whose final clinical results were unknown were excluded from the analysis. After excluding seven patients, 110 patients were finally included in this study, and 26.4% (*n*=29) had DM ([Fig. 1](#F1){ref-type="fig"}).

Data collection and definitions
-------------------------------

The patients\' electronic medical records were reviewed. Data on patients\' age, sex, comorbidities, symptoms, vital signs, radiological findings, severity based on the National Early Waring Score (NEWS), treatment, and clinical outcomes were collected. DM was defined as any of the following criteria: (1) a known history of diabetes; (2) taking oral or injected antihyperglycemic agents; (3) history of abnormal blood glucose levels based on diagnostic criteria for type 2 DM of the Korean Diabetes Association \[[@B10]\]. Data on glycosylated hemoglobin (HbA1c) level, DM duration, oral antihyperglycemic agents (OHAs), insulin, and renin-angiotensin system (RAS) inhibitors were collected from patients with DM.

NEWS \[[@B11]\] is an early warning score facilitating the early detection of and response to deterioration of patient\'s condition and consists of seven parameters: pulse oximetry, oxygen, pulse, systolic blood pressure, respiration rate, temperature, and central nervous system status. Each parameter is assigned a score of 0 to 3 points. The score reflects the degree to which the parameters differ from the normal range.

Acute respiratory distress syndrome (ARDS) was diagnosed according to the Berlin definition \[[@B12]\]. Septic shock was defined according to the Third International Consensus Definitions for sepsis and septic shock (Sepsis-3) \[[@B13]\]. Acute cardiac injury was defined as a serum troponin I level above the 99th percentile upper reference limit or new abnormal electrocardiography and echocardiography findings \[[@B14]\]. Acute kidney injury was defined according to the Kidney Disease Improving Global Guidelines (KDIGO) for acute kidney injury \[[@B15]\].

In this study, we used the term "severe and critical outcome (SCO)" as an index of poor clinical outcome. SCO was defined as the composite outcome of ARDS, septic shock, intensive care unit (ICU) care, and 28-day mortality, referring to the classification of the Chinese Center for Disease Control and Prevention \[[@B2]\].

Statistical analysis
--------------------

Continuous variables are expressed as mean±standard deviation and were compared by Student\'s *t*-test or the Mann-Whitney *U* test. Categorical variables were compared by the chi-squared test or Fisher\'s exact test. To determine the effects of DM and medications on SCO, multiple logistic regression analysis was performed after adjusting for covariates. In all analyses, two-tailed *P*\<0.05 was taken to indicate statistical significance. All statistical analyses were performed using SPSS software version 24.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

Baseline characteristics and clinical outcomes of COVID-19 patients according to the presence of DM
---------------------------------------------------------------------------------------------------

[Table 1](#T1){ref-type="table"} shows the baseline characteristics of all patients and a comparison of patients with and without DM. The mean age of the total patient population was 56.9 years and the male to female ratio was 1:1.3. Smokers accounted for 14.5%. A total of 29 patients had DM (26.4%). DM patients had a higher mean age than patients without DM (*n*=81) (66.3±8.9 years vs. 53.5±17.9 years, respectively; *P*\<0.001). Systolic and diastolic blood pressures were higher in patients with DM than in those without DM (both *P*\<0.05). Hypertension was the most common comorbidity among all participants (33.6%), and more than half of the DM patients had a diagnosis or were taking medication for hypertension. On physical examination, there were no differences in symptoms between groups, except headaches were more frequent among non-DM patients (*P*=0.020). Bilateral pneumonia was common in DM patients, but the difference in radiologic findings (unilateral pneumonia, bilateral pneumonia, and multiple ground-glass opacity) compared to non-DM patients was not statistically significant (*P*=0.191). DM patients had higher white blood cell counts, neutrophil counts, lactate dehydrogenase, serum glucose, and C-reactive protein levels and lower albumin level compared to non-DM patients (all *P*\<0.05).

[Table 2](#T2){ref-type="table"} shows the severity, clinical outcomes, and treatment strategy of COVID-19 patients with and without DM. DM patients, compared to subjects without DM, had higher NEWS (4.0±4.2 vs. 1.9±2.1, *P*=0.015) and rates of progression to mortality (17.2% vs. 1.2%), ARDS (37.9% vs. 8.6%), septic shock (24.1% vs. 1.2%), ICU care (27.6% vs. 6.2%), and acute cardiac injury (27.6% vs. 6.2%) (all *P*\<0.01). In addition, DM patients had higher rates of oxygen and invasive mechanical ventilation treatments (both *P*\<0.01) and prescription of hydroxychloroquine medication (*P*=0.022).

The rates of progression to SCO were significantly higher with patients aged ≥70 years old compared to subjects \<70 years old (42.3% vs. 9.6%, *P*=0.01), and in DM patients compared to subjects without DM (44.8% vs. 7.5%, *P*\<0.001). The effect of age and DM on the risk of SCO in COVID-19 was analyzed ([Fig. 2A](#F2){ref-type="fig"}). After adjustments for age, sex, smoking status, and the presence of comorbidities, age of ≥70 years old (odds ratio \[OR\], 7.106; *P*=0.005) and DM (OR, 10.771; *P*\<0.001) significantly increased the risk of SCO, whereas hypertension, chronic lung disease, and malignancy had no effect on severity of outcomes.

Analysis of factors affecting SCO in COVID-19 patients with DM
--------------------------------------------------------------

We extracted diabetic patients (*n*=29) and explored the effects of age, DM control status, and medications on clinical outcomes. Twelve were newly diagnosed with DM on admission. Comparisons of clinical characteristics and outcomes according to age with a cutoff of 70 years are presented in [Table 3](#T3){ref-type="table"}. Compared to DM patients \<70 years old (*n*=18), older DM patients (≥70 years old, *n*=11) were significantly older (60.9±6.2 years vs. 75.3±3.6 years, respectively; *P*\<0.001) but there was no difference in sex ratio (*P*=0.702). The HbA1c and serum glucose levels, DM duration, and medication histories of OHAs, insulin and RAS inhibitors were not different between groups (all *P*\>0.05). NEWS was not different between groups (3.3±4.1 vs. 5.3±4.5, respectively; *P*=0.204), but SCO was more frequent in DM patients ≥70 years old (27.8% vs. 72.7%, respectively; *P*=0.027).

The effects of age, HbA1c, and serum glucose level on SCO in COVID-19 patients with DM were evaluated ([Fig. 2B](#F2){ref-type="fig"}). After adjustments, age significantly increased the risk of SCO (OR, 1.175; *P*=0.014), whereas HbA1c and serum glucose had no effect on SCO. We also evaluated the effects of medications on SCO, acute cardiac injury, and acute kidney injury in COVID-19 patients with DM ([Fig. 3](#F3){ref-type="fig"}). The usage of metformin or RAS inhibitors had no effect on SCO, but RAS inhibitors showed protective effects against acute cardiac injury (OR, 0.048; *P*=0.045).

We investigated whether poor glycemic control affects the prognosis of COVID-19 patients ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). Compared to diabetic patients with HbA1c \<8% (*n*=21), poorly controlled (HbA1c ≥8%, *n*=8) patients had higher levels of HbA1c (6.9±0.5 vs. 10.0±1.9, respectively) and serum glucose (163.9±56.0 vs. 266.4±133.5, respectively), and had longer duration of DM (2.5±3.9 vs. 11.4±12.5, respectively) (all *P*\<0.05). However, age, sex ratio, medication histories, NEWS, and SCO were not different between groups (all *P*\>0.05).

DISCUSSION
==========

The results of the present study showed that the elderly over 70 years old and the presence of DM significantly impacted the clinical course of COVID-19. Patients with DM showed higher severity scores (NEWS) and more frequently progressed to SCO than patients without DM. Among DM patients, age significantly affected SCO, and RAS inhibitors showed beneficial effects against acute cardiac injury.

In recent reports of COVID-19 from China, the prevalence of comorbid DM was 7.4% to 20%, and patients with cardiometabolic disease had a severe clinical course \[[@B16]\]. Various results have been reported as to whether DM is a significant risk factor for disease progression of COVID-19. Guo et al. \[[@B9]\] reported higher levels of inflammation-related biomarkers in DM patients compared to non-DM patients. Zhou et al. \[[@B17]\] reported significant numbers of patients with DM in the non-survivor group, but the presence of DM did not significantly increase the risk of mortality. Wu et al. \[[@B8]\] reported that, after 40 days of follow-up, the presence of DM increased the risk of progressing to ARDS but did not affect mortality rate. In the present study, patients with DM had high levels of inflammation-related biomarkers and increased risk of SCO, including 28-day mortality. These data indicate that special attention should be paid to COVID-19 patients with comorbid DM.

The impacts of DM on the clinical course of SARS and Middle East respiratory syndrome (MERS) have been verified previously. The presence of DM and fasting plasma glucose level ≥126 mg/dL increased the risk of death in SARS by 6.3 and 3.3 times, respectively, and emphasized that adequate blood glucose control during treatment could improve prognosis \[[@B18]\]. In a meta-analysis in MERS cases, DM patients had 1.8 times increased risk of death \[[@B19]\]. In diabetic mice exposed to MERS-CoV, the duration of the severe disease phase was prolonged and the recovery was delayed, independently of viral titer, which was due to dysregulation of the immune response \[[@B20]\]. Previous reports and the results of the present study indicated that the progression of COVID-19 is also affected by DM.

Angiotensin-converting enzyme 2 (ACE2) acts as a cellular receptor for SARS-CoV and SARS-CoV2 \[[@B21]\], enabling acute viral replication. Accordingly, the causes of increased susceptibility to COVID-19 in diabetic patients was suggested to be related to diminished T cell function, increased susceptibility to cytokine storm, and increased ACE2 expression \[[@B22]\]. In addition, there is emerging evidence that the usage of drugs that increase ACE2 expression, such as RAS inhibitors (ACE inhibitors and angiotensin II receptor blockers), thiazolidinediones, and ibuprofen, may accelerate the development of COVID-19 \[[@B23]\]. In addition, glucagon like peptide-1 agonist \[[@B24]\] and atorvastatin \[[@B25]\] upregulate ACE2, so they should be used with caution. In the case of MERS-CoV, dipeptidyl peptidase 4 (DPP4) was shown to be a functional cellular receptor \[[@B26]\], so it was suggested that the use of DPP4 inhibitors may slow the progression of COVID-19 infection \[[@B27]\]. In the present study, neither RAS inhibitors nor metformin exacerbated the course of COVID-19, so the discontinuation or modification of these drugs does not appear to be necessary.

This study had some limitations. First, we included only our experience in a single tertiary center in Korea and recognize that there are limitations to generalizing these findings to other situations. However, the proportion of moderate to high-risk (NEWS ≥5) patients among the participants in this study was about 20%, which was a similar pattern to those of previous studies. Amidst the global pandemic of COVID-19, each country and city is showing quite different outcomes, depending on their healthcare systems and resources \[[@B28]\]. These findings may provide insight for the operation of healthcare systems that are similar to those of South Korea. Second, we cannot exclude the effects of glycemic control or DM complications on prognosis of COVID-19 patients. There are no data regarding the optimal glycemic target for patients with COVID-19 and DM, and our study only showed the clinical outcomes according to HbA1c level. In the present study, the poorly controlled group, as defined by HbA1c ≥8%, did not show different outcomes with regard to severity or mortality. Surprisingly, however, we found that about 40% of the patients in the DM group had been newly diagnosed with DM, indicating heterogeneity within the DM group. Further large-scale studies on glycemic control and COVID-19 prognosis would provide more insight. Meanwhile, healthcare providers should pay attention to the possibility of "hidden diabetes" in COVID-19 patients.

This study had some strengths. To our knowledge, this is the first study suggesting effects of antidiabetic medications or glycemic control (indicated by HbA1c) on the clinical course of COVID-19. These findings provide insight into factors that affect the course of COVID-19 in patients with DM. In contrast to concerns raised previously, OHA and RAS inhibitors did not significantly affect the severity of COVID-19, suggesting that patients with DM do not have to stop taking their medications.

In conclusion, COVID-19 patients with DM had higher severity and higher rates of severe outcomes, including 28-day mortality, than those without DM. After adjustment for other risk factors, DM was an independent risk factor for SCO in COVID-19 patients. Among patients with DM, older age significantly increased the risk of SCO but RAS inhibitors and OHA did not affect the outcomes. Given these potentially devastating effects of DM, especially in older patients, intensive and aggressive monitoring is needed in COVID-19.
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Supplementary materials related to this article can be found online at <https://doi.org/10.4093/dmj.2020.0105>.

###### Supplement Table 1

Comparison of clinical characteristics and outcomes in coronavirus disease 2019 patients with controlled (HbA1c \<8%) vs. poorly controlled (HbA1c ≥8%) diabetes

![Patient selection. COVID-19, coronavirus disease 2019; DM, diabetes mellitus.](dmj-44-405-g001){#F1}

![Diabetes mellitus (DM) and age as a risk factor for severe and critical outcomes in patients with coronavirus disease 2019. Severe and critical outcomes: composite outcome of acute respiratory distress syndrome, septic shock, intensive care unit care, and mortality within 28 days. Multivariate logistic regression analysis was adjusted by (A) age (\<70:≥70 years old), sex, smoking status, and the presence of comorbidities (diabetes mellitus, hypertension, chronic lung disease, and malignancy) in the total number of patients and (B) age (continuous), sex, smoking status, and glycosylated hemoglobin (HbA1c), and serum glucose levels among diabetic patients. The odds ratios (ORs) are presented in log10. CI, confidence interval.](dmj-44-405-g002){#F2}

![Effects of (A) metformin and (B) RAS inhibitors on severe and critical outcomes, acute cardiac injury, and acute kidney injury in diabetic patients with coronavirus disease 2019. Severe and critical outcomes: composite outcome of acute respiratory distress syndrome, septic shock, intensive care unit care, and mortality within 28 days. Multivariate logistic regression analysis was adjusted by age, sex, smoking status, and glycosylated hemoglobin level. The odds ratios (ORs) are presented in log10. CI, confidence interval.](dmj-44-405-g003){#F3}

###### Comparison of baseline anthropometric, symptom, and laboratory characteristics between coronavirus disease 2019 patients with and without diabetes

![](dmj-44-405-i001)

  Variable                            All patients (*n*=110)   With DM (*n*=29)   Without DM (*n*=81)   *P* value
  ----------------------------------- ------------------------ ------------------ --------------------- -----------
  Age, yr                             56.9±17.0                66.3±8.9           53.5±17.9             \<0.001
  Male sex                            48 (43.6)                14 (48.3)          34 (42.0)             0.664
  Smoker                              16 (14.5)                7 (24.1)           9 (11.1)              0.123
   Packs per year                     29.2±26.7                26.6±17.9          31.2±32.9             0.918
  Vital signs on admission                                                                              
   Body temperature, ℃                37.2±0.7                 37.1±0.7           37.2±0.6              0.501
   Heart rate, beats/min              86.0±13.8                86.8±15.2          85.7±13.3             0.719
   Respiratory rate                   21.0±2.8                 22.1±4.4           20.6±1.9              0.085
   Systolic BP, mm Hg                 128.1±18.6               136.2±19.9         125.2±17.4            0.006
   Diastolic BP, mm Hg                79.9±12.2                84.0±13.2          78.5±11.6             0.038
  Comorbidities                                                                                         
   Hypertension                       37 (33.6)                16 (55.2)          21 (25.9)             0.006
   Chronic lung disease               4 (3.6)                  2 (6.9)            2 (2.5)               0.283
   Malignancy                         6 (5.5)                  2 (6.9)            4 (4.9)               0.653
   Cardiovascular disease             10 (9.1)                 5 (17.2)           5 (6.2)               0.125
   Cerebrovascular disease            4 (3.6)                  3 (10.3)           1 (1.2)               0.055
  Symptoms on admission                                                                                 
   Fever                              62 (56.4)                16 (55.2)          46 (56.8)             1.000
   Cough                              58 (52.7)                11 (37.9)          47 (58.0)             0.083
   Sputum                             38 (34.5)                7 (24.1)           31 (38.3)             0.183
   Myalgia                            37 (33.6)                8 (27.6)           29 (35.8)             0.497
   Dyspnea                            37 (33.6)                12 (41.4)          25 (30.9)             0.362
   Headache                           26 (23.6)                2 (6.9)            24 (29.6)             0.020
   Diarrhea                           11 (10.0)                1 (3.4)            10 (12.3)             0.282
  Radiological findings                                                                                 0.191
   Unilateral pneumonia               17 (15.5)                2 (6.9)            15 (18.5)             
   Bilateral pneumonia                46 (41.8)                18 (62.1)          28 (34.6)             
   Multiple ground-glass opacity      39 (35.5)                9 (31.0)           30 (37.0)             
  Laboratory results                                                                                    
   White blood cell count, ×10^9^/L   6.7±3.3                  7.8±2.9            6.3±3.4               0.040
   Neutrophil count, ×10^9^/L         4.7±3.3                  6.0±3.1            4.3±3.3               0.022
   Platelets, ×10^9^/L                244.1±103.5              237.7±92.0         246.3±107.8           0.700
   Albumin, g/dL                      3.7±0.6                  3.4±0.6            3.9±0.5               \<0.001
   Lactate dehydrogenase, IU/L        625.9±331.7              801.4±453.3        559.0±243.7           0.010
   Serum glucose, mg/dL               133.6±61.8               192.1±94.2         112.7±20.3            \<0.001
   eGFR, mL/min/1.73 m^2^(MDRD)       89.9±23.5                82.6±23.8          92.5±23.0             0.050
   C-reactive protein, mg/dL          5.8±8.4                  9.9±10.2           4.3±7.1               0.011
   Procalcitonin, ng/mL               0.5±2.6                  1.2±4.6            0.2±1.3               0.260

Values are presented as mean±standard deviation or number (%).

DM, diabetes mellitus; BP, blood pressure; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease.

###### Comparison of clinical outcomes and treatment between coronavirus disease 2019 patients with and without diabetes

![](dmj-44-405-i002)

  Variable                All patients (*n*=110)   With DM (*n*=29)   Without DM (*n*=81)   *P* value
  ----------------------- ------------------------ ------------------ --------------------- -----------
  Severity scoring                                                                          
   NEWS                   2.5±3.0                  4.0±4.2            1.9±2.1               0.015
  Clinical outcomes                                                                         
   28-day mortality       6 (5.5)                  5 (17.2)           1 (1.2)               0.005
   ARDS                   18 (16.4)                11 (37.9)          7 (8.6)               0.001
   Septic shock           8 (7.3)                  7 (24.1)           1 (1.2)               \<0.001
   ICU care               13 (11.8)                8 (27.6)           5 (6.2)               0.005
   Acute cardiac injury   13 (11.8)                8 (27.6)           5 (6.2)               0.005
   Acute kidney injury    9 (8.2)                  5 (17.2)           4 (4.9)               0.052
  Treatment                                                                                 
   Oxygen                 38 (34.5)                18 (62.1)          20 (24.7)             0.001
   HFNC                   10 (9.1)                 4 (13.8)           6 (7.4)               0.451
   IMV                    11 (10.0)                8 (27.6)           3 (3.7)               0.001
   CRRT                   3 (2.7)                  2 (6.9)            1 (1.2)               0.169
   ECMO                   4 (3.6)                  3 (10.3)           1 (1.2)               0.055
   Antibiotics            108 (98.2)               27 (93.1)          81 (100.0)            0.068
   Lopinavir/ritonavir    106 (96.4)               27 (93.1)          79 (97.5)             0.283
   Hydroxychloroquine     91 (82.7)                28 (96.6)          63 (77.8)             0.022
   Glucocorticoid         21 (19.1)                8 (27.6)           13 (16.0)             0.270

Values are presented as mean±standard deviation or number (%).

NEWS, National Early Warning Score; ARDS, acute respiratory distress syndrome; ICU, intensive care unit; HFNC, high flow nasal cannula; IMV, invasive mechanical ventilation; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation.

###### Comparison of clinical characteristics and outcomes between younger (\<70 years) and older (≥70 years) coronavirus disease 2019 patients with diabetes

![](dmj-44-405-i003)

  Variable                         Age \<70 yr (*n*=18)   Age ≥70 yr (*n*=11)   *P* value
  -------------------------------- ---------------------- --------------------- -----------
  Age, yr                          60.9±6.2               75.3±3.6              \<0.001
  Male sex                         9 (50)                 4 (36.4)              0.702
  HbA1c, %                         7.8±1.7                7.36±2.0              0.611
  Serum glucose, mg/dL             178.9±69.0             213.6±126.1           0.465
  DM duration, yr                  2.8±4.4                9.0±11.6              0.133
  Newly diagnosed DM               9 (50.0)               3 (27.3)              0.317
  Medications                                                                   
   Oral anti-hyperglycemic drugs                                                
    No medication                  10 (58.8)              3 (30.0)              0.236
    On Medication                  7 (41.2)               7 (70.0)              
     Metformin                     6 (35.3)               5 (50.0)              0.687
     DPP4i                         5 (29.4)               1 (10.0)              0.363
     Sulfonylurea                  2 (11.8)               2 (20.0)              0.613
     Others (TZD, SGLT2i, AGI)     2 (11.8)               2 (20.0)              0.613
   Insulin                         1 (10.0)               0                     0.675
   RAS inhibitors                  8 (47.1)               6 (60.0)              0.695
  NEWS                             3.3±4.1                5.3±4.5               0.204
  Severe and critical outcome^a^   5 (27.8)               8 (72.7)              0.027

Values are presented as mean±standard deviation or number (%).

HbA1c, glycosylated hemoglobin; DM, diabetes mellitus; DPP4i, dipeptidyl peptidase 4 inhibitor; TZD, thiazolidinedione; SGLT2i, sodium-glucose transport protein 2 inhibitor; AGI, α-glucosidase inhibitor; NEWS, National Early Warning Score.

^a^Composite outcome of acute respiratory distress syndrome, septic shock, intensive care unit care, and mortality within 28 days.
